Dr Yann-Alexandre Vano speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the NIVOREN study.

The NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab for patients with metastatic clear-cell renal cell carcinoma (mccRCC) in a “real world setting”.

Dr Vano outlines the results which give correlations for outcomes with nivolumab.

He outlines the way this study can be adapted in the future, and when can be learnt from these initial exploratory results.